News Releases

October 26, 2017
Research & Development highlights: MP0250:  Phase 2 study in Multiple Myeloma progressing well and according to plan MP0250:  FDA accepted the company’s IND (submitted in August 2017) for phase 2 study evaluating MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC); on track to dose
Displaying 161 - 170 of 183
* These releases may contain price sensitive information